SeaStar Medical Holding Corp - ICU STOCK NEWS

SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced the issuance of U.S. Patent No. 11,866,730 for its Selective Cytopheretic Device (SCD) to treat subjects with inflammatory conditions. The SCD is a first-in-class, cell-directed extracorporeal therapy that selectively targets highly active inflammatory cells to quell the inflammatory response. This patent significantly fortifies the company's intellectual property portfolio and supports its strategy to validate the technology’s application across multiple high-value clinical indications. CEO Eric Schlorff highlighted the importance of controlling uncontrolled hyperinflammation, which can lead to vital organ damage and even death. The SCD therapy works to selectively target the most highly activated cells responsible for inflammation to potentially reverse the damage they cause. The newly issued patent covers methods for using SCD cartridges to treat inflammatory conditions by extracorporeally sequestering activated leukocytes and/or platelets and inhibiting or deactivating their inflammatory action, as well as methods for processing activated leukocytes and/or platelets. The patent’s claimed methods require the SCD cartridge to have specific ratios of surface area for sequestering activated leukocytes and/or platelets to SCD inner volume. Unlike pathogen removal and other blood-purification tools, the SCD selectively targets the most highly activated proinflammatory neutrophils and monocytes.